688298
vs
S
Shanghai Composite
688298
Over the past 12 months, Zhejiang Orient Gene Biotech Co Ltd has underperformed Shanghai Composite, delivering a return of -15% compared to the Shanghai Composite's +23% growth.
Stocks Performance
688298 vs Shanghai Composite
Performance Gap
688298 vs Shanghai Composite
Performance By Year
688298 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Zhejiang Orient Gene Biotech Co Ltd
Glance View
Zhejiang Orient Gene Biotech Co., Ltd. engages in the research, development, production and sales of in vitro diagnostic products. The company is headquartered in Huzhou, Zhejiang and currently employs 1,895 full-time employees. The company went IPO on 2020-02-05. The firm's main products are Point of Care Testing (POCT) instant diagnostic reagents, which are mainly used in drug testing, infectious disease testing, eugenic testing, tumor marker testing and cardiac marker testing. The firm also engages in the manufacture and sales of biochemical diagnostic reagents used for dry biochemical diagnostics and biochemical fluid diagnostics. The firm operates its businesses in Mainland China, America, Europe, Asia, Africa and Oceania.
